SCHEMBL2365728

SCHEMBL2365728

COCC1COC(=O)N1c1ccc(C(=O)N2CCN(c3nc(C)c(C)cc3C)CC2)cn1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADRA1A P35348 3/20 0.40
EGLN1 Q9GZT9 9/20 0.39
PIK3CA P42336 1/20 0.38
ALDH1A1 P00352 3/20 0.36
RAB9A P51151 2/20 0.36
KMT2A Q03164 2/20 0.35
NPC1 O15118 1/20 0.35
KDM4E B2RXH2 2/20 0.35
POLB P06746 1/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
HSD17B10 Q99714 1/20 0.35
MEN1 O00255 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
CFTR P13569 1/20 0.34
MAPT P10636 1/20 0.34
PKM P14618 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2365720 1.00 ADRA1A (0.40) ADRA1AEGLN1PIK3CAALDH1A1RAB9A
SCHEMBL2366024 0.92 ALDH1A1 (0.39) EGLN1ALDH1A1RAB9AKMT2ANPC1
SCHEMBL2366032 0.92 ALDH1A1 (0.39) EGLN1ALDH1A1RAB9AKMT2ANPC1
SCHEMBL2366897 0.89 ADRA1A (0.40) ADRA1AEGLN1PIK3CAALDH1A1RAB9A
SCHEMBL2366903 0.89 ADRA1A (0.40) ADRA1AEGLN1PIK3CAALDH1A1RAB9A
SCHEMBL2366365 0.88 PIK3CA (0.39) PIK3CAALDH1A1KMT2AKDM4EPOLB
SCHEMBL2366372 0.88 PIK3CA (0.39) PIK3CAALDH1A1KMT2AKDM4EPOLB
SCHEMBL2366424 0.86 ADRA1A (0.40) ADRA1AEGLN1PIK3CAALDH1A1RAB9A
SCHEMBL2366419 0.86 ADRA1A (0.40) ADRA1AEGLN1PIK3CAALDH1A1RAB9A
SCHEMBL2366217 0.82 ADRA1A (0.40) ADRA1AEGLN1PIK3CAALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364975-B1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORP (JP) 2013-06-12 EP disclosed
US-8354401-B2 Oxazolidinone amide aromatic compounds for supressing MMP-9 production MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-01-15 US disclosed
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-27 US disclosed
EP-2364975-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2011-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP2 ADRA1A 4758/4885EGLN1 128/4885PIK3CA 4648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.